Onzemipgene parvec clinical trials
Also written HMR59, JNJ-81201887 and AAVCAGsCD59.
How each study uses onzemipgene parvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the onzemipgene parvec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Janssen Research & Development, LLC (4) · Hemera Biosciences (1)
Studies
Open first, then newest update. How each study uses onzemipgene parvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)RecruitingPhase 2/3Janssen Research & Development, LLCNCT06635148Written as JNJ-81201887
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)CompletedPhase 2Janssen Research & Development, LLCNCT05811351Written as JNJ-81201887
- Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59CompletedPhase 1Janssen Research & Development, LLCNCT03144999Written as AAVCAGsCD59
- AAVCAGsCD59 for the Treatment of Wet AMDCompletedPhase 1Janssen Research & Development, LLCNCT03585556Written as Intravitreal AAVCAGsCD59
- Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)WithdrawnPhase 2Hemera BiosciencesNCT04358471Written as Intravitreal AAVCAGsCD59
Codes
What other systems call onzemipgene parvec · ClinicalTrials.gg INT018386
- UNII (FDA) WU56BNE7AUONZEMIPGENE PARVECOne source FDA
- NCI Thesaurus C215264Onzemipgene ParvecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WU56BNE7AU | ONZEMIPGENE PARVEC | One source FDA |
| NCI Thesaurus | C215264 | Onzemipgene Parvec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.